OpGen (OPGN) and Editas Medicine (NASDAQ:EDIT) Head-To-Head ComparisonWeek HeraldIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid … Continue reading
Synthetic Biology Market Technology Growth, New Factor, Latest TrendThe FinancialHTF MI published a new industry research that focuses on Synthetic Biology market and delivers in-depth market analysis and future prospects of Global Synthetic Biology ma… Continue reading
Stocks GalleryReviewing Editas Medicine (EDIT) & ArQule (NASDAQ:ARQL)The Lincolnian OnlineIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribo… Continue reading
中国种业商务网作科所新技术有望大幅加快农作物基因功能研究和精准育种进程中国种业商务网CRISPR/Cas介导的植物基因组定点编辑、单碱基替换和同源重组体系的建立和利用，将在农作物基因功能研究和精准育种中发挥重要作用，展现了广阔的发展潜力和应用前景。CRISPR/Cpf1作为CRISPR/Cas系统的新成员，更简单 … Continue reading
StockNewsTimesHead to Head Review: BeyondSpring (NASDAQ:BYSI) versus Editas Medicine (EDIT)StockNewsTimesIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a p… Continue reading
Doctor explains life-saving kidney cancer immunotherapyKSLA-TVThe first sign something was terribly wrong was two blood clots Mark Lanier coughed up while driving one day in April of 2014. As a nurse, he knew his health was in serious jeopardy and imme… Continue reading
Orlando Sentinel |
Mount Dora boy among first to receive approved gene therapy drug for eye disease
Orlando Sentinel Last December, the FDA approved Spark Therapeutics’ gene therapy drug Luxturna, a one-time injection in the eye for treatment of the specific mutation. “That was an exciting and emotional time,” St. Pierre-Pettit said. Bascom Palmer Eye Institute … MDNN: American Health Trends, the First-Ever Gene Therapy Procedure, and the President’s Stance on OpioidsMD Magazine |
The Pharma Letter |
First ‘off-the-shelf’ stem cell therapy gains central authorization in EU
The Pharma Letter Japanese pharma company Takeda Pharmaceutical (TYO: 4502) and the Belgian biopharma that it is in the process of acquiring, TiGenix, achieved a notable milestone on Friday with the European Commission’s approval of Alofisel (darvadstrocel). It has been … Stem cell therapy approved in Europe to treat fistulizing Crohn’s diseaseHealio |